DUBLIN, Oct. 20, 2021 /PRNewswire/ -- Theravance
Biopharma, Inc. (NASDAQ: TBPH), will report its third quarter 2021
financial results and provide a business update after market close
on Wednesday, November 3, 2021. An
accompanying conference call and simultaneous webcast will be
hosted at 5:00 pm ET (2:00 pm PT/9:00 pm
IST) that day.
Conference Call Information
To participate in the live
call by telephone, please dial (855) 296-9648 from the US or (920)
663-6266 for international callers, using the confirmation code
9772385. Those interested in listening to the conference call live
via the internet may do so by visiting Theravance Biopharma's
website at www.theravance.com, under the Investors section,
Presentations and Events.
A replay of the conference call will be available on Theravance
Biopharma's website for 30 days through December 3, 2021. An audio replay will also be
available through 7:00 pm ET on
November 10, 2021 by dialing (855)
859-2056 from the US, or (404) 537-3406 for international callers,
and then entering confirmation code 9772385.
About Theravance Biopharma
Inc. is a biopharmaceutical company primarily focused on the
discovery, development and commercialization of respiratory
medicines. Its core purpose is to create medicines that help
improve the lives of patients suffering from respiratory
In pursuit of its purpose, Theravance Biopharma leverages
decades of respiratory expertise to discover and develop
transformational medicines that make a difference. These efforts
have led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution
indicated for the maintenance treatment of patients with chronic
obstructive pulmonary disease (COPD). Its respiratory pipeline of
internally discovered programs is targeted to address significant
patient respiratory needs.
Theravance Biopharma has an economic interest in potential
future payments from Glaxo Group Limited or one of its affiliates
(GSK) pursuant to its agreements with Innoviva, Inc. relating to
certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and
the Cross/Star logo are registered trademarks of the Theravance
Biopharma group of companies (in the U.S. and certain other
YUPELRI® is a registered trademark of Mylan Specialty
L.P., a Viatris Company. Trademarks, trade names or service marks
of other companies appearing on this press release are the property
of their respective owners.
Gail Cohen, Corporate Communications
917-214-6603 / firstname.lastname@example.org
View original content to download
SOURCE Theravance Biopharma, Inc.